JP2021521132A5 - - Google Patents
Info
- Publication number
- JP2021521132A5 JP2021521132A5 JP2020555192A JP2020555192A JP2021521132A5 JP 2021521132 A5 JP2021521132 A5 JP 2021521132A5 JP 2020555192 A JP2020555192 A JP 2020555192A JP 2020555192 A JP2020555192 A JP 2020555192A JP 2021521132 A5 JP2021521132 A5 JP 2021521132A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- amino
- prevention
- treatment
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18166490.5 | 2018-04-10 | ||
| EP18166490 | 2018-04-10 | ||
| PCT/EP2019/058398 WO2019197244A1 (en) | 2018-04-10 | 2019-04-03 | A substituted oxopyridine derivative |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521132A JP2021521132A (ja) | 2021-08-26 |
| JP2021521132A5 true JP2021521132A5 (enExample) | 2023-05-16 |
| JP7333336B2 JP7333336B2 (ja) | 2023-08-24 |
Family
ID=61965754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555192A Active JP7333336B2 (ja) | 2018-04-10 | 2019-04-03 | 置換オキソピリジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11884660B2 (enExample) |
| EP (1) | EP3774796B1 (enExample) |
| JP (1) | JP7333336B2 (enExample) |
| KR (1) | KR102858566B1 (enExample) |
| CN (1) | CN111902414B (enExample) |
| AU (1) | AU2019251699B2 (enExample) |
| BR (1) | BR112020018237A2 (enExample) |
| CA (1) | CA3096480A1 (enExample) |
| DK (1) | DK3774796T3 (enExample) |
| ES (1) | ES2922533T3 (enExample) |
| IL (1) | IL277811B2 (enExample) |
| MX (1) | MX2020010635A (enExample) |
| PE (1) | PE20210165A1 (enExample) |
| SA (1) | SA520420308B1 (enExample) |
| SG (1) | SG11202008352YA (enExample) |
| WO (1) | WO2019197244A1 (enExample) |
| ZA (1) | ZA202006963B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
| CN116947818B (zh) * | 2023-09-18 | 2023-12-19 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| US9475809B2 (en) | 2013-07-23 | 2016-10-25 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| WO2015063093A1 (de) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| WO2015120777A1 (zh) | 2014-02-14 | 2015-08-20 | 四川海思科制药有限公司 | 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用 |
| WO2016046158A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| WO2016046166A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| JP6517925B2 (ja) | 2014-09-24 | 2019-05-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたオキソピリジン誘導体 |
| ES2716417T3 (es) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica |
| WO2016046156A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| ES2712886T3 (es) | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
| CA2979937A1 (en) | 2015-03-19 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| EP3344618A1 (de) | 2015-09-04 | 2018-07-11 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| CN113912586B (zh) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
-
2019
- 2019-04-03 DK DK19715095.6T patent/DK3774796T3/da active
- 2019-04-03 AU AU2019251699A patent/AU2019251699B2/en active Active
- 2019-04-03 CA CA3096480A patent/CA3096480A1/en active Pending
- 2019-04-03 KR KR1020207028399A patent/KR102858566B1/ko active Active
- 2019-04-03 MX MX2020010635A patent/MX2020010635A/es unknown
- 2019-04-03 WO PCT/EP2019/058398 patent/WO2019197244A1/en not_active Ceased
- 2019-04-03 IL IL277811A patent/IL277811B2/en unknown
- 2019-04-03 EP EP19715095.6A patent/EP3774796B1/en active Active
- 2019-04-03 PE PE2020001563A patent/PE20210165A1/es unknown
- 2019-04-03 CN CN201980023665.5A patent/CN111902414B/zh active Active
- 2019-04-03 US US17/046,004 patent/US11884660B2/en active Active
- 2019-04-03 BR BR112020018237-0A patent/BR112020018237A2/pt not_active Application Discontinuation
- 2019-04-03 SG SG11202008352YA patent/SG11202008352YA/en unknown
- 2019-04-03 JP JP2020555192A patent/JP7333336B2/ja active Active
- 2019-04-03 ES ES19715095T patent/ES2922533T3/es active Active
-
2020
- 2020-10-08 SA SA520420308A patent/SA520420308B1/ar unknown
- 2020-11-09 ZA ZA2020/06963A patent/ZA202006963B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4933730B2 (ja) | 転写因子調節化合物およびその使用法 | |
| JP6518683B2 (ja) | 抗真菌化合物の調製方法 | |
| KR20220026538A (ko) | 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체 | |
| WO2007007919A3 (en) | Heterocyclic janus kinase 3 inhibitors | |
| WO2007011833A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
| EP3114109A1 (en) | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) | |
| NO20081482L (no) | Delta- og epsilon-krystallformer for imatinibmesylat | |
| JP2015024998A5 (enExample) | ||
| NO20091560L (no) | Biaryleterureaforbindelser | |
| WO2008002244A8 (en) | Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3) | |
| JP2011502153A5 (enExample) | ||
| CN105085428B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| JP2019089811A (ja) | 抗真菌化合物の調製方法 | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| TW200800957A (en) | New compounds | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| JP2003516987A5 (enExample) | ||
| NO20091254L (no) | Terapeutiske sammensetninger | |
| WO2007056219A3 (en) | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | |
| TWI617553B (zh) | 吖丁啶基氧苯基吡咯啶化合物 | |
| MA46268B1 (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| EP2266969A3 (en) | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | |
| WO2019224774A1 (en) | Heterocyclic amides as rip1 kinase inhibitors |